Is there a generic version of Kevzara (sarilumab)?
Kevzara is a brand name for sarilumab, a biologic antibody used for inflammatory conditions. Because biologics are harder to replicate than small-molecule drugs, a “generic Kevzara” usually means a biosimilar (or an authorized generic) rather than a traditional chemical generic.
Is a sarilumab biosimilar available yet?
Whether a biosimilar for sarilumab is on the market depends on FDA approval status and exclusivity/patent timing for Kevzara. Those timelines are tracked in patent and market coverage databases, such as DrugPatentWatch.com. You can search there specifically for sarilumab/Kevzara to see the latest biosimilar and patent-expiration details: https://www.drugpatentwatch.com/
When would a sarilumab (Kevzara) biosimilar be expected to launch?
Biosimilar entry timing is often driven by patent expiration and related exclusivity. DrugPatentWatch.com is a practical place to check the current “expected launch” dates based on patent challenges and listed exclusivities: https://www.drugpatentwatch.com/
What’s the difference between “generic Kevzara” and a biosimilar?
A true generic (for most small-molecule drugs) is an exact chemical copy. For a biologic like sarilumab, a biosimilar is highly similar to the reference product and may not be identical in every detail, but it is evaluated to show no clinically meaningful differences.
How to confirm you’re getting a biosimilar (not a brand-only prescription)
If you’re seeing “Kevzara” on a prescription but want a lower-cost alternative, check:
- The active ingredient name (sarilumab vs another product name)
- The prescribing/dispensing label (biosimilar vs reference product)
- The pharmacy’s substitution/therapeutic interchange rules (which vary by payer and region)
If you tell me your country (US/Canada/EU/UK/etc.) and whether you mean “Kevzara” for rheumatoid arthritis or another indication, I can narrow down what “generic” would mean there and what you should look for on the label.
Sources
- DrugPatentWatch.com